Cargando…

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease

Although immunotherapies against the amyloid-β (Aβ) peptide tried so date failed to prove sufficient clinical benefit, Aβ still remains the main target in Alzheimer’s disease (AD). This article aims to show the rationale of a new therapeutic strategy: clearing Aβ from the CSF continuously (the “CSF-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menendez-Gonzalez, Manuel, Padilla-Zambrano, Huber S., Alvarez, Gabriel, Capetillo-Zarate, Estibaliz, Tomas-Zapico, Cristina, Costa, Agustin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911461/ https://www.ncbi.nlm.nih.gov/pubmed/29713273 http://dx.doi.org/10.3389/fnagi.2018.00100

Ejemplares similares

New, Fully Implantable Device for Selective Clearance of CSF-Target Molecules: Proof of Concept in a Murine Model of Alzheimer’s Disease
por: Coto-Vilcapoma, María Almudena, et al.
Publicado: (2022)

Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson’s Disease
por: Menéndez-González, Manuel, et al.
Publicado: (2018)

Linking Plasma Amyloid Beta and Neurofilament Light Chain to Intracortical Myelin Content in Cognitively Normal Older Adults
por: Fernandez-Alvarez, Marina, et al.
Publicado: (2022)

Degradation of Alzheimer's amyloid fibrils by microglia requires delivery of ClC-7 to lysosomes
por: Majumdar, Amitabha, et al.
Publicado: (2011)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Mangiferin and Morin Attenuate Oxidative Stress, Mitochondrial Dysfunction, and Neurocytotoxicity, Induced by Amyloid Beta Oligomers
por: Alberdi, Elena, et al.
Publicado: (2018)

Automation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
por: Kollhoff, Alexander L., et al.
Publicado: (2018)

CSF-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients with Alzheimer's Dementia Spectrum
por: Behzad, Maryam, et al.
Publicado: (2023)

Amyloid β / PKC-dependent alterations in NMDA receptor composition are detected in early stages of Alzheimer´s disease
por: Ortiz-Sanz, Carolina, et al.
Publicado: (2022)

Accumulation of Intraneuronal β-Amyloid 42 Peptides Is Associated with Early Changes in Microtubule-Associated Protein 2 in Neurites and Synapses
por: Takahashi, Reisuke H., et al.
Publicado: (2013)

Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?
por: Menéndez González, Manuel
Publicado: (2017)

Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer's Disease
por: Luchena, Celia, et al.
Publicado: (2018)

Corrigendum to “Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer's Disease”
por: Luchena, Celia, et al.
Publicado: (2019)

A Neuron, Microglia, and Astrocyte Triple Co-culture Model to Study Alzheimer’s Disease
por: Luchena, Celia, et al.
Publicado: (2022)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
por: Alcolea, Daniel, et al.
Publicado: (2019)

Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease
por: Li, Yi, et al.
Publicado: (2022)

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
por: Cheignon, C., et al.
Publicado: (2017)

Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent
por: Pascale, Crissey L, et al.
Publicado: (2011)

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2012)

Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
por: Huber, Colin M., et al.
Publicado: (2017)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?
por: Menendez-Gonzalez, Manuel, et al.
Publicado: (2019)

Expression of the beta-amyloid transporter, LRP-1, in aging choroid plexus: implications for the CSF-brain system in NPH and Alzheimer's disease
por: Johanson, Conrad, et al.
Publicado: (2006)

Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease
por: Lopez-Font, Inmaculada, et al.
Publicado: (2015)

CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease
por: Boumenir, Adla, et al.
Publicado: (2019)

Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease
por: Xiang, Yang, et al.
Publicado: (2015)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

Amyloid Beta Dynamics in Biological Fluids—Therapeutic Impact
por: Schreiner, Thomas Gabriel, et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Amyloid-beta immunotherapy: the hope for Alzheimer disease?
por: Barrera-Ocampo, Alvaro, et al.
Publicado: (2016)

Dissociation of amyloid biomarkers in PET and CSF in Alzheimer’s disease: a case report
por: Schroeter, Matthias L., et al.
Publicado: (2015)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

CSF β-amyloid and white matter damage: unravelling the neuropathology of Alzheimer’s disease
por: Sousa Alves, Gilberto
Publicado: (2018)

Tracing of temporo-entorhinal connections in the human brain: cognitively impaired argyrophilic grain disease cases show dendritic alterations but no axonal disconnection of temporo-entorhinal association neurons
por: Thal, Dietmar Rudolf, et al.
Publicado: (2007)

Infectious origin of Alzheimer’s disease: Amyloid beta as a component of brain antimicrobial immunity
por: Vojtechova, Iveta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_10kok7o28g215j65g9gi2j1tui